Video Corner
Video Corner
Watch Our Webcasts on YouTube
On Immunic‘s YouTube channel, you can watch our latest webcasts and conference calls, including public update and earnings calls, presentations from scientific and medical events, and updates on our clinical development programs.
2024
Immunic, Inc. Q3 2024 Earnings Call Recording
Immunic ENSURE Program: Positive Outcome Interim Futility Analysis Recording
Immunic MS RnD Day New York City Recording
Immunic, Inc. Q2 2024 Earnings Call Recording
Immunic, Inc. Q1 2024 Earnings Call Recording
Immunic MS R&D Day San Francisco Recording
Immunic, Inc. Q4 and Year End 2023 Earnings Call Recording
2023
Immunic, Inc. Q3 2023 Earnings Call Recording
Immunic Vidofludimus Calcium CALLIPER Interim Data Recording
Immunic, Inc. Q2 2023 Earnings Call Recording
Immunic Celiac Disease KOL Roundtable Recording
Immunic, Inc. Q1 2023 Earnings Call Recording
Immunic IMU-856 Celiac Disease Phase 1b Data Recording
Immunic CALDOSE-1 Maintenance Data of Vidofludimus Calcium in UC and Pipeline Update Recording
Immunic, Inc. Q4 2022 Earnings Call Recording
Immunic Celiac Disease R&D Webcast Recording
2022
Immunic Multiple Sclerosis R&D Webcast Recording
Immunic, Inc. Q3 2022 Earnings Call Recording
Immunic, Inc. IMU-856 Phase 1 SAD MAD Data Healthy Human Subjects Webcast Recording
Immunic, Inc. Q2 2022 Earnings Call Recording
8th Joint ACTRIMS-ECTRIMS Meeting: Poster Presentation Dr. Robert Fox
Immunic CALDOSE-1 Phase 2 Top-Line Data in Ulcerative Colitis and Corporate Update Webcast Recording
Immunic Company Presentation @ BioEquity Europe 2022
Immunic, Inc. Q1 2022 Earnings Call Recording
2021
Watch Our Video Interviews on Proactive Investors
Proactive Investors is a financial news platform that delivers business and finance news to a global investment audience. Via the following links, you can watch our latest video and audio interviews with Immunic’s management team members.
2024
Immunic CSO discusses breaking the IBD stigma to mark Crohn’s and Colitis Awareness Week
Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal
Immunic CEO details progress following productive third quarter
Immunic’s Jessica Breu talks BIO-Europe & MS research advancements
Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials
Immunic CMO on key ECTRIMS highlights and MS research
Immunic Thearapeutics Presents Advanced MS Treatment Data at Global Conference
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies
Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial
Immunic CEO discusses Q2 results & MS trials update
Immunic CSO outlines progress with MS therapies to mark World Brain Day
Immunic CEO Daniel Vitt discusses rise in autoimmune diseases and MS treatments
Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic CEO Dr Daniel Vitt provides hope for sufferers during Celiac Awareness Month
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic CMO details programs aimed at alleviating multiple sclerosis during UK’s MS Awareness Week
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
Immunic reports successful 2023 and prepares for key 2025 milestones
Immunic CSO highlights her role ahead of International Day of Women and Girls in Science
Immunic says $240M financing shows confidence in Phase 2 CALLIPER study as it targets unmet MS needs
Immunic kicks off 2024 with massive fundraise
2023
Immunic focusing on business development during Q4
Immunic CSO hails “great” progress with MS program
Immunic “super excited” about latest PMS trial data
Immunic CEO hails “great day” after completing IMU-838 phase 2 trial enrolment
Immunic CEO says Q2 results “couldn’t be better”
Immunic Inc eyeing “big step” for multiple sclerosis patients
Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases
Immunic ultimately hoping to “offer patients a new kind of treatment” for multiple sclerosis
Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program
Immunic Inc set to bring relief with encouraging results
Immunic IMU-856 trial data “clearly goes beyond” initial expectations
Immunic gets a “positive surprise” from lead asset trial
Immunic Therapeutics taking a “unique approach” in biopharma
Immunic CSO discusses breaking the IBD stigma to mark Crohn’s and Colitis Awareness Week
https://www.proactiveinvestors.com/companies/news/1061862/immunic-cso-discusses-breaking-the-ibd-stigma-to-mark-crohn-s-and-colitis-awareness-week-1061862.html
Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal
https://www.proactiveinvestors.co.uk/companies/news/1060545/immunic-announces-publication-of-imu-856-phase-1-trial-data-in-peer-reviewed-journal-1060545.html
Immunic, Inc. Q3 2024 Earnings Call Recording
https://www.youtube.com/watch?v=Jg0OrheALEQ
Immunic CEO details progress following productive third quarter
https://www.proactiveinvestors.co.uk/companies/news/1060088/immunic-ceo-details-progress-following-productive-third-quarter-1060088.html
Immunic’s Jessica Breu talks BIO-Europe & MS research advancements
https://www.proactiveinvestors.co.uk/companies/news/1059905/immunic-s-jessica-breu-talks-bio-europe-ms-research-advancements-1059905.html
Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials
https://www.proactiveinvestors.co.uk/companies/news/1058982/immunic-therapeutics-cmo-dr-andreas-muehler-on-positive-interim-analysis-for-rms-trials-1058982.html
Immunic ENSURE Program: Positive Outcome Interim Futility Analysis Recording
https://www.youtube.com/watch?v=JvINIdkTxgI
Immunic CMO on key ECTRIMS highlights and MS research
https://www.proactiveinvestors.co.uk/companies/news/1057131/immunic-cmo-on-key-ectrims-highlights-and-ms-research-1057131.html
Immunic Thearapeutics Presents Advanced MS Treatment Data at Global Conference
https://www.proactiveinvestors.co.uk/companies/news/1056447/immunic-therapeutics-presents-advanced-ms-treatment-data-at-global-conference-1056447.html
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies
https://www.proactiveinvestors.co.uk/companies/news/1056195/immunic-ceo-discusses-new-york-ms-r-d-day-potential-of-vidofludimus-calcium-and-ms-studies-1056195.html
